临床药师参与一日一次氨基糖苷类抗菌药物抗感染治疗的药学监护实践

Abstract
Figure/Table
References (33)
Related Citation (5)

Download: PDF (579 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the safety of aminoglycoside antibiotics once daily with clinical pharmacists tracking the entire treatment process. Metheds From September 2015 to August 2016, in Institute of Antibiotics, Shanghai Huashan Hospital, 30 patients who used once daily aminoglycoside antibiotics were selected, clinical pharmacist participated in the formulation of treatment strategies, and monitored the adverse effects of aminoglycosides. Clinical pharmacists observed the serum creatinine, blood urea nitrogen and hearing of the patients before and after using aminoglycosides. Results The serum creatinine and serum urea nitrogen in 30 patients after treatment with aminoglycoside antibiotics had no significant change compared with that before treatment, and the differences were not statistically significant (P > 0.05). In addition, none of the 30 patients appeared ototoxicity or neuromuscular blockade. Conclusion Under the supervision of clinical pharmacists, once daily using of aminoglycoside antibiotics and control the infusion rate according to the instructions have a better safety, and the incidence of nephrotoxicity, ototoxicity, neuromuscular blockage and other adverse reactions is low.

Key words： Clinical pharmacists Aaminoglycosides Ototoxicity Nephrotoxicity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Jinchun ZHANG Haixia MENG Xiangyan GE Weihong▲

Cite this article:

LIU Jinchun ZHANG Haixia MENG Xiangyan GE Weihong▲. Exploration of the safety of aminoglycosides once daily by clinical pharmacist[J]. 中国医药导报, 2018, 15(17): 171-174.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I17/171

[1] Pitiriga V，Dimitroulia E，Saroglou G，et al. The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? [J]. Expert Rev Anti Infect Ther，2017，15（10）：947-954.
[2] Zobell JT，Epps K，Kittell F，et al. Tobramycin and beta-lactam antibiotic use in cystic fibrosis exacerbations：a pharmacist approach [J]. J Pediatr Pharmacol Ther，2016， 21（3）：239-246.
[3] Poulikakos P，Falagas ME. Aminoglycoside therapy in infectious diseases [J]. Expert Opin Pharmacother，2013，14（12）： 1585-1597.
[4] 胡付品，郭燕，朱德妹，等.2016年CHINET细菌耐药性监测[J].中国感染与化疗杂志，2017，17（5）：481-491.
[5] Xu A，Zheng B，Xu YC，et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013 [J]. Clin Microbiol Infect，2016，22（Suppl 1）：s1-s8.
[6] 王振远，郭玉华.分析常用抗菌药物的给药时间以及临床合理用药情况[J].世界最新医学信息文摘，2018，18（3）：98.
[7] Lorenzo MP，Housman EL，Housman ST. Once-daily aminoglycosides [J]. Am J Health Syst Pharm，2016，73（8）：529-530.
[8] LeBras M，Chow I，Mabasa VH，et al. Systematic Review of efficacy，pharmacokinetics，and administration of intraventricular aminoglycosides in adults [J]. Neurocrit Care，2016，25（3）：492-507.
[9] Yagi K，Ishii M，Namkoong H，et al. The efficacy，safety，and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases [J]. BMC Infect Dis，2017，17（1）：558.
[10] Miura K，Nakagawa M，Takahashi H，et al. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies [J]. Int J Hematol，2016，103（3）：334-340.
[11] Ashwlayan VD，Singh G. Analysis of aminoglycosides [J]. Int J Pharm Sci Rev Res，2016，39（1）：282-293.
[12] Cohen R，Raymond J，Launay E，et al. Antimicrobial treatment of urinary tract infections in children [J]. Arch Pediatr，2017，24（12S）：S22-S25.
[13] Bush PW，Ashby DM，Guharoy R，et al. Pharmacy practice model for academic medical centers [J]. Am J Health Syst Pharm，2010，67（21）：1856-1861.
[14] Alomi YA，Almudaiheem HY. Clinical and economic outcomes of pharmacist intervention during therapeutic drug monitoring program in Saudi Arabia [J]. Value Health，2016，19（7）：A465-A466.
[15] 何洪静，张红菊，夏培元.临床药师在抗菌药物合理应用中的作用探讨[J].中国药房，2011，22（26）：2408-2410.
[16] 刘斌，王忠元.临床药师在抗菌药物临床应用管理中的作用[J].社区医学杂志，2017，15（15）：25-27.
[17] 万明.临床药师在临床合理用药中的作用分析[J].临床合理用药，2017，10（8A）：27-28.
[18] Wargo KA，Edwards JD. Aminoglycoside-induced nephrotoxicity [J]. J Pharm Pract，2014，27（6）：573-577.
[19] Badve SV，Hawley CM，McDonald SP，et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function [J]. Nephrol Dial Transplant，2012，27（1）：381-387.
[20] Fraisse T，Gras Aygon C，Paccalin M，et al. Aminoglycosides use in patients over 75 years old [J]. Age Ageing，2014，43（5）：676-681.
[21] Giri VP，Giri OP，Bajracharya S，et al. Risk of acute kidney injury with amikacin versus gentamycin both in combination with metronidazole for surgical prophylaxis [J]. J Clin Diagn Res，2016，10（1）：FC09-12.
[22] Randjelovic P，Veljkovic S，Stojiljkovic N，et al. Gentamicin nephrotoxicity in animals： Current knowledge and future perspective s[J]. Excli J，2017，16：388-399.
[23] Mcwilliam SJ，Antoine DJ，Smyth RL，et al. Aminoglycoside-induced nephrotoxicity in children [J]. Pediatr Nep-hrol，2017，32（11）：2015-2025.
[24] Jiang M，Karasawa T，Steyger PSS. Aminoglycoside-induced cochleotoxicity：a review [J]. Front Cell Neurosci，2017，11：308.
[25] Jiang M，Taghizadeh F，Steyger PS. Potential mechanisms underlying inflammation-enhanced aminoglycoside-induced cochleotoxicity [J]. Front Cell Neurosci，2017，11：362.
[26] Karasawa T，Steyger PS. Intracellular mechanisms of aminoglycoside-induced cytotoxicity [J]. Integr Biol （Camb），2011，3（9）：879-886.
[27] O′Sullivan ME，Perez A，Lin R，et al. Towards the prevention of aminoglycoside-related hearing loss [J]. Front Cell Neurosci，2017，11：325.
[28] Kocyigit I，Vural A，Unal A，et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis [J]. Eur Arch Otorhinolaryngol，2015，272（10）：2611-2620.
[29] 李明阳，李勇，王昉彤，等.氨基糖苷类抗生素肾毒性及生物标志物的研究进展[J].中国抗生素杂志，2014，39（2）：85-88.
[30] Drusano GL，Louie A. Optimization of aminoglycoside therapy [J]. Antimicrob Agents Chemother，2011，55（6）：2528-2531.
[31] Pasquale TR，Tan JS. Nonantimicrobial effects of antibacterial agents [J]. Clin Infect Dis，2005，40（1）：127-135.
[32] 王美霞.氨基糖苷类药物的不良反应及综合防治对策[J].中国实用医药，2016，11（2）：269-270.
[33] Stankowicz MS，Ibrahim J，Brown DL. Once-daily aminoglycoside dosing：an update on current literature [J]. Am J Health Syst Pharm，2015，72（16）：1357-1364.